Corrigendum to “Nitric Oxide Precursors and Dimethylarginines as Risk Markers for Accelerated Measured GFR Decline in the General Population” [Kidney International Reports Volume 8, Issue 4, April 2023, Pages 818-826]
Nikoline B. Rinde, Inger Therese Enoksen, Toralf Melsom, Ole Martin Fuskevåg, Bjørn Odvar Eriksen, Jon Viljar Norvik
Abstract
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRenal and Vascular Pathologies
The authors regret that there was a small error in the calculation of iohexol clearance (mGFR) in the third round of the Renal Iohexol Clearance Survey (RENIS-3).
The reported mean was 82.7 (15.0) mL/min/1.73 m^2^, but the revised mean (SD) should be 82.6 (14.4) mL/min/1.73 m^2^.
Corrected Tables 2 and 3 are shown below.Table 2. Linear mixed model regression analyses of the associations between dimethylarginines, nitric oxide precursors and their ratios with measured glomerular filtration rate change rates (N=1407)Independent variableModel 1Model 2Model 3mL/min/1.73m^2^ per year per SD∗ (95% CI)P-valuemL/min/1.73m^2^ per year per SD∗ (95% CI)P-valuemL/min/1.73m^2^ per year per SD∗ (95% CI)P-valueADMA0.01 (-0.05 to 0.07)0.720.01 (-0.05 to 0.07)0.730.02 (-0.05 to 0.08)0.59SDMA0.08 (0.01 to 0.14)0.020.07 (0.01 to 0.14)0.020.08 (0.01 to 0.14)0.02Arginine-0.04 (-0.11 to 0.02)0.17-0.04 (-0.11 to 0.02)0.17-0.05 (-0.11 to 0.02)0.16Citrulline-0.03 (-0.09 to 0.04)0.42-0.03 (-0.09 to 0.04)0.40-0.02 (-0.08 to 0.05)0.59Ornithine-0.05 (-0.12 to 0.01)0.10-0.05 (-0.12 to 0.01)0.10-0.04 (-0.11 to 0.02)0.17Each row represents a separate regression model.∗ A negative coefficient indicates a steeper decline.Model 1: crude.Model 2: adjusted for age, sex, and BMI.Model 3: model 2 and adjusted for systolic blood pressure, use of angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, diuretics, calcium blockers, beta-blockers, or other antihypertensive medications (yes/no), fasting glucose, smoking status (yes/no), C-reactive protein and albumin creatinine ratio.Abbreviations: ADMA, asymmetric dimethylarginine; Arg, arginine; OR, odds ratio; SD, standard deviation; SDMA, symmetric dimethylarginine.Table 3. Associations of biomarkers with accelerated GFR decline defined as the 10% with the steepest GFR decline rateIndependent variableModel 1Model 2Model 3OR per SD (95% CI)P-valueOR per SD (95% CI)P-valueOR per SD (95% CI)P-valueADMA1.10 (0.93-1.31)0.261.12 (0.93-1.35)0.231.10 (0.89-1.35)0.37SDMA0.94 (0.79-1.13)0.511.13 (0.91-1.40)0.281.22 (0.97-1.55)0.09Arginine1.27 (1.07-1.50)0.0071.17 (0.97-1.40)0.091.04 (0.85-1.27)0.72Citrulline1.25 (1.05-1.48)0.0101.44 (1.18-1.75)<0.0011.35 (1.09-1.68)0.007Ornithine1.35 (1.15-1.58)<0.0011.34 (1.12-1.60)0.0011.21 (0.99-1.48)0.07Each row represents a separate regression model.Model 1: crude.Model 2: adjusted for age, sex, BMI, and baseline GFR.Model 3: model 2 and adjusted for systolic blood pressure, use of angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, diuretics, calcium blockers, beta-blockers, or other antihypertensive medications (yes/no), fasting glucose, smoking status (yes/no), C-reactive protein and albumin creatinine ratio.Abbreviations: ADMA, asymmetric dimethylarginine; Arg, arginine; GFR, glomerular filtration rate; OR, odds ratio; SD, standard deviation; SDMA, symmetric dimethylarginine.
The authors would like to apologize for any inconvenience caused.
DOI of original article: https://doi.org/10.1016/j.ekir.2023.01.015